Norris Medicines Limited (BOM:524414)
16.34
+0.76 (4.88%)
At close: Aug 18, 2026
Norris Medicines Revenue
Norris Medicines had revenue of 9.25M INR in the quarter ending June 30, 2026, a decrease of -36.50%. This brings the company's revenue in the last twelve months to 75.77M, up 15.64% year-over-year. In the fiscal year ending March 31, 2026, Norris Medicines had annual revenue of 81.32M with 39.72% growth.
Revenue (ttm)
75.77M
Revenue Growth
+15.64%
P/S Ratio
2.06
Revenue / Employee
2.30M
Employees
33
Market Cap
155.81M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 81.32M | 23.12M | 39.72% |
| Mar 31, 2025 | 58.20M | 1.85M | 3.27% |
| Mar 31, 2024 | 56.36M | -27.23M | -32.58% |
| Mar 31, 2023 | 83.59M | -10.80M | -11.44% |
| Mar 31, 2022 | 94.38M | -28.13M | -22.96% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Add-Shop E-Retail | 1.71B |
| Beryl Drugs | 215.51M |
| Unjha Formulations | 152.79M |
| Zenith Healthcare | 107.48M |
| Hamps Bio | 84.75M |
| Desh Rakshak Aushdhalaya | 66.33M |
| Colinz Laboratories | 58.11M |
| Emmessar Biotech & Nutrition | 23.78M |